SEC Form 4 · accession 0001662252-17-000220
Xenetic Biosciences, Inc. · XBIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey F Eisenberg
Officer — CEO · Director
Period of report
Oct 26, 2017
Accepted (ET)
Oct 30, 2017 · 9:09 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001534525
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Oct 26, 2017 | A | 50,000 | $0.00 | A | 50,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionsF2 | $2.11 | Oct 26, 2017 | A | 250,000 | A | — | Oct 26, 2027 | Common Stock | 250,000 | 250,000 | D |
Explanation of responses
- F1This represents the grant of a restricted stock unit ("RSU") award. Each RSU represents the right to receive one share of the Issuer's common stock at vesting. The shares underlying the RSUs will vest and become exercisable as follows: one-third on the first anniversary of October 26, 2017 (the "Vesting Start Date"); one-third on the second anniversary of the Vesting Start Date; and one-third on the third anniversary of the Vesting Start Date.
- F2The shares underlying the option will vest and become exercisable as follows: 41,666 shares shall vest on the first anniversary of October 26, 2017 (the "Vesting Start Date"); 41,667 shares shall vest on the second anniversary of the Vesting Start Date; 41,667 shares shall vest on the third anniversary of the Vesting Start Date; 100,000 shares shall vest upon the achievement of key clinical milestones for XBIO-101; and 25,000 shares shall vest upon the achievement of key development milestones related to PSA. The Reporting Owner may not exercise any of the shares under the option if and until the Issuer receives shareholder approval of an increase in the number of shares of common stock authorized under the Company's equity incentive plan on or prior to October 11, 2018.